Tools
Fluoxetine
Indications
FDA-Approved Indications
Fluoxetine has received FDA approval to treat major depressive disorder (8 and older), obsessive-compulsive disorder (7 and older), panic disorder (with or without agoraphobia), bulimia nervosa, depressive episodes associated with Bipolar I disorder (as an adjunct with olanzapine), and treatment-resistant depression when used in combination with olanzapine.[1][2][3]
The American Psychiatric Association guidelines recommend fluoxetine as first-line pharmacotherapy (along with CBT) for patients with bulimia nervosa.[4]
Off-Label Uses
Non-FDA-approved uses for fluoxetine include binge eating disorder, social anxiety disorder, premenstrual dysphoric disorder, borderline personality disorder, Raynaud phenomenon, and selective mutism.[5][6]
The American Psychological Association endorses fluoxetine for post-traumatic stress disorder (PTSD).[7]
Mechanism of Action
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Mechanism of Action
Serotonin and norepinephrine, both biological amines, have been shown to play a role in the treatment of depression. Low concentrations of serotonin appear in the cerebrospinal fluid of patients with depression. Additionally, lower numbers of serotonin uptake sites are located on the platelets of patients with depression. Presynaptic serotonin (5-HT1A) receptors are located in the dorsal raphe nucleus, which project to the prefrontal cortex. Fluoxetine exerts its antidepressant effects by blocking the reuptake of serotonin in the presynaptic serotonin neurons by blocking the reuptake transporter protein in the presynaptic terminal. Fluoxetine also has mild activity at the 5-HT2A and 5-HT2C receptors.
Fluoxetine has minimal activity on noradrenergic reuptake. Due to the drug's action on the reuptake of serotonin, fluoxetine produces an activating effect, and due to its long half-life, the initial antidepressant effect emerges within 2 to 4 weeks.
Pharmacokinetics
Absorption: Peak plasma concentrations of fluoxetine are attained after 6 to 8 hours. Fluoxetine is well absorbed with a bioavailability of 70% to 90%. Food does not appear to impact the bioavailability of fluoxetine, but it may slow its absorption by 1 to 2 hours, which is not clinically significant. Thus, fluoxetine may be administered with or without food.
Distribution: Fluoxetine has plasma protein binding of approximately 94.5%, bound to albumin and alpha-1 glycoprotein. Fluoxetine readily crosses the blood-brain barrier, with a brain-to-plasma ratio of 2.6:1 in humans. The volume of distribution (Vd) of fluoxetine and its metabolite ranges between 20 to 42 L/kg. Some studies report that fluoxetine has the maximum volume of distribution (Vd) of any SSRI (between 14 and 100 L/kg).[8]
Metabolism: Fluoxetine's active metabolite is norfluoxetine, produced when the cytochrome P450 enzyme (CYP2D6) acts on it. Prescribers must remember that fluoxetine has several drug-drug interactions due to its metabolism through the CYP2D6 isoenzyme. Additionally, norfluoxetine can have an inhibitory effect on CYP3A4. Fluoxetine has a half-life of 2 to 4 days, and its active metabolite norfluoxetine has a half-life of 7 to 9 days.[9][10] Approximately 7% of individuals definitively exhibit poor metabolism of fluoxetine due to reduced activity of CYP2D6.[11]
Elimination: Fluoxetine and norfluoxetine have long elimination half-lives, leading to the presence of the drug in the body for several weeks, even after stopping its use. This has important implications when discontinuing fluoxetine and prescribing medications that may interact with fluoxetine and norfluoxetine after discontinuation. The metabolism of fluoxetine is extensive, resulting in approximately 2.5% of the administered dose being excreted unchanged in the urine.[12]
Administration
Available Dosage Forms and Strengths
Fluoxetine should be administered once a day, either in the morning or evening and started at 20 mg daily. Fluoxetine is only available in an oral formulation as an oral solution (20 mg/5 mL), tablet (10 mg, 20 mg, 60 mg), capsule (10 mg, 20 mg, 40 mg), and delayed-release capsule (90 mg).
Fluoxetine is also available in a fixed-dose combination with olanzapine (6 mg olanzapine with 25 mg fluoxetine). Considering that the medication can be efficacious at doses of 5 mg and weighing in on the adverse effect profile, it is essential to note that the drug can be administered in a smaller dosage. For an individual with poorly tolerated adverse effects, the fluoxetine may be dosed in 10 mg tablets instead of 20 mg to help minimize any adverse effects. Generally, 20 mg to 40 mg daily dosing is required to be effective for most individuals.
It also comes in a delayed-release capsule formulation with a dosage of 90 mg per week. Evidence suggests that the efficacy of the delayed-release formulation (90 mg once weekly) is similar to that of individuals receiving fluoxetine 20 mg daily. Compared to other SSRIs, fluoxetine is not associated with the emergence of abrupt withdrawal symptoms (eg, sleep disturbances, dysphoria, fever, nausea) seen with other antidepressants due to prolonged half-life.[13][14]
Adult Dosing
Major depressive disorder: The typical starting dose of fluoxetine for major depressive disorder (MDD) is 20 mg daily. The maximum recommended dose of fluoxetine for MDD is 80 mg daily.[15]
Obsessive-compulsive disorder: The starting dose of fluoxetine for obsessive-compulsive disorder (OCD) is 20 mg daily. The typical maintenance dose for OCD is 20 to 60 mg.
Bulimia nervosa: The American Psychiatric Association guidelines recommend cognitive-behavioral therapy as the primary treatment for adults with bulimia nervosa. If there is minimal or no response to psychotherapy alone within 6 weeks, prescribing 60 mg of fluoxetine daily is recommended.[4]
Panic disorder: The typical starting dose of fluoxetine for panic disorder is 10 mg daily. After 1 week, consider increasing the fluoxetine to 20 mg daily. The maximum recommended dose of fluoxetine for panic disorder is 60 mg daily.
Special Patient Populations
Hepatic impairment: In patients with liver cirrhosis, the clearance of fluoxetine and its active metabolite (norfluoxetine) decreases, thus increasing the elimination of half-lives of these substances. Therefore, a lower/less frequent dose of fluoxetine should be used in patients with cirrhosis. In addition, caution is warranted when using fluoxetine in patients with diseases or conditions that could affect its metabolism.
Renal impairment: No dose adjustment of fluoxetine is required in patients with renal impairment. A study suggests that directly observed, once-weekly fluoxetine could be a feasible and well-tolerated treatment option for hemodialysis patients.[16]
Pregnancy considerations: Fluoxetine is categorized as Pregnancy Category C medicine. In the late third trimester, neonates exposed to SSRIs, including fluoxetine, have developed complications requiring prolonged hospitalization, tube feeding, and respiratory support. Complications of temperature instability, feeding difficulty, vomiting, respiratory distress, apnea, cyanosis, hypoglycemia, hypotonia, hypertonia, constant crying, hyperreflexia, tremor, jitteriness, irritability, and seizures are reported. These symptoms could precipitate right at delivery and are consistent with either a drug discontinuation syndrome or a direct toxic effect of SSRIs.The clinician may consider tapering fluoxetine in the third trimester.[17]
Breastfeeding considerations: As fluoxetine is excreted in human milk, nursing while on fluoxetine is not recommended.[17] If a woman used fluoxetine during pregnancy, most experts recommend against changing medications while breastfeeding. Otherwise, agents with lower excretion into breast milk may be preferred, especially while nursing a newborn or preterm infant. In addition, the breastfed infant should be monitored for behavioral adverse effects such as agitation, colic, irritability, poor feeding, and poor weight gain.[18]
Pediatric patients: Fluoxetine is FDA-approved for administration in pediatric patients with MDD and OCD. As with other SSRIs, decreased weight gain is associated with administering fluoxetine in children and adolescent patients. The dose for children with MDD and OCD is 10 mg once daily. According to the AACAP (American Academy of Child and Adolescent Psychiatry), it is recommended to offer selective serotonin reuptake inhibitor (SSRI) medication, particularly fluoxetine, to children and adolescents diagnosed with major depressive disorder. For those who respond positively to acute treatment with fluoxetine, AACAP suggests continuing with fluoxetine alone or combining it with cognitive-behavioral therapy to prevent the relapse or recurrence of major depressive disorder.[19]
Extensive metareview study results show that fluoxetine offers a strong risk-benefit ratio compared to other antidepressants in youth. This finding suggests that fluoxetine could be recommended as the initial treatment of choice for depressive disorders in children and adolescents.[20]
Older patients: Fluoxetine is effective for major depressive disorder in older patients.[21] The usual starting dose of fluoxetine is 10 mg once daily; it can be increased to 20 mg as tolerated.
Adverse Effects
The most common adverse effects reported by adults include insomnia, nausea, diarrhea, anorexia, dry mouth, headache, drowsiness, anxiety, nervousness, yawning, bruising, seizures, bleeding (rarely), hyperhidrosis, induction of mania, rare activation of suicidal ideation and behavior (especially in teenagers), weight gain/loss, decreased orgasm (anorgasmia and ejaculation latency), muscle weakness, tremors, and pharyngitis.[22][23]
The 5-HT2C antagonism is thought to contribute to the anxiety, insomnia, and agitation patients perceive with fluoxetine. Patients may even have a panic attack with the administration of fluoxetine. Thus, the clinician's responsibility is to educate patients.
Most adverse effects are immediate and disappear with time. Thus, waiting for the side effects to subside is best before altering treatment. Most adverse effects are dose-dependent and time-dependent. Clinicians must exercise caution against the emergence of agitation or activation, which may indicate a bipolar state and require the addition of a mood stabilizer or an atypical antipsychotic. Fluoxetine can be activating; if insomnia is present, consider dosing early in the morning. Additionally, the dose may be reduced if the side effects are too distressing. The patient should be cautioned about adverse effects; if they persist, switching to a different antidepressant may be indicated after a few weeks.[24]
Reversible cerebral vasoconstriction syndrome presenting with a severe headache has been associated with fluoxetine.[25] A rare case report describes chorea induced by fluoxetine.[26] Rabbit syndrome is distinguished by rapid, fine, and rhythmic movements along the vertical axis of the mouth, usually due to antipsychotics. A case report of rabbit syndrome due to fluoxetine in a child with obsessive-compulsive disorder has been reported.[27]
It is best to try another antidepressant before relying on augmentation strategies. This approach can minimize polypharmacy and encourage adherence to psychotropic medications. Trazodone, mirtazapine, or a hypnotic may be options for insomnia. Mirtazapine may also help with agitation or gastrointestinal adverse effects. Benzodiazepines may be used to treat anxiety. Bupropion or a phosphodiesterase inhibitor (such as sildenafil) may address sexual dysfunction. Bupropion may also be an option for potential cognitive slowing or apathy seen with fluoxetine.
Drug-Drug Interactions
Fluoxetine inhibits CYP2D6, an enzyme responsible for metabolizing drugs like TCAs, antipsychotics, and antiarrhythmics, and increases the serum concentration of the drugs.[12]
Tricyclic antidepressants: Using fluoxetine concurrently with tricyclic antidepressants (TCAs) can increase levels of TCAs. This may require adjusting the TCA dosage.
Antipsychotics: SSRIs, including fluoxetine, can increase the concentration of haloperidol and clozapine.[28] Coingestion of aripiprazole and fluoxetine can predispose to prolongation of the QT interval.[29]
Antiarrhythmic medications: Simultaneous use of fluoxetine with Class 1A antiarrhythmic medications like quinidine, procainamide, and Class III antiarrhythmics like amiodarone and sotalol can increase the QT interval.[30]
Benzodiazepines: Fluoxetine can increase the plasma concentration of alprazolam and diazepam. Signs of sedation and impaired psychomotor function should be monitored.[31]
Warfarin: Among SSRIs, fluoxetine has one of the highest drug-drug interaction risks with warfarin. Use with caution due to the increased risk of bleeding. Clinicians should monitor the PT/INR.[32]
NSAIDs: Concurrent use of fluoxetine with NSAIDs/aspirin increases the risk of upper gastrointestinal bleeding.[33]
Warfarin: The concurrent use of fluoxetine with SNRIs or SSRIs and warfarin can increase the anticoagulant effects of warfarin, leading to increased bleeding risk. Warfarin should be used cautiously, and the PT/INR should be monitored.[32]
Anticonvulsants: The simultaneous administration of fluoxetine with anticonvulsants like phenytoin or carbamazepine can increase plasma concentration, requiring therapeutic drug monitoring (TDM).[34]
Serotonergic agents: Fluoxetine, especially in combination with other serotonergic medications, can lead to serotonin syndrome. These drugs include triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John's Wort. If any symptoms of serotonin syndrome occur, discontinuing fluoxetine and providing supportive treatment is recommended.[35]
Contraindications
Contraindications to fluoxetine include hypersensitivity to fluoxetine or any component in its formulation. This drug is also contraindicated with the concurrent use of monoamine oxidase inhibitors (current use of MAOI or within 2 weeks of discontinuing the MAOI) due to the risk of serotonin syndrome.
Never initiate fluoxetine in a patient receiving linezolid.[36]
Do not give fluoxetine with pimozide or thioridazine due to the risk of QT prolongation.[37]
Use this agent with caution in those with a history of seizures or older patients.
Boxed Warnings
There is a warning for suicidal ideations in those treated with fluoxetine, especially in younger children and adults 18 to 24 years old.[38] Parents and caregivers should be advised to closely monitor patients for any changes in behavior within the first 2 months after initiating warfarin therapy.[39]
Warning and Precautions
Pregnancy: Fluoxetine is not recommended for use during pregnancy. However, depending on the scenario, treatment may be necessary during pregnancy. A risk/benefit analysis merits careful consideration during therapy with fluoxetine in pregnancy. Fluoxetine exposure early in pregnancy may be associated with an increased risk of septal heart defects.[40][41]
The use of the medication beyond 20 weeks is associated with pulmonary hypertension in the newborn, although this is definitively not proven. Exposure to fluoxetine late in pregnancy may correlate with the risk of gestational hypertension and preeclampsia. Additionally, trace amounts of the drug may appear in breast milk.
Electroconvulsive therapy: Case reports of seizures have been reported in patients administered electroconvulsive therapy (ECT) while on fluoxetine treatment. Caution should be exercised when prescribing fluoxetine to individuals with a history of seizures.[42][43]
Allergic reactions and rash: If patients develop a rash or any signs of an allergic reaction appear, fluoxetine should be stopped. Fluoxetine-induced Stevens-Johnson syndrome has been reported.[44]
Activation of mania/hypomania: Patients should be evaluated for bipolar disorder before starting fluoxetine, as it can trigger manic or hypomanic episodes. Close monitoring for any mood changes is necessary during treatment.[45]
Anxiety and insomnia: Some patients may experience increased anxiety and insomnia while taking fluoxetine.[24]
Angle-closure glaucoma: Fluoxetine may cause angle-closure glaucoma. Monitor IOP in patients with a history of glaucoma.[46]
Hyponatremia: In rare cases, fluoxetine has been associated with low sodium levels (hyponatremia) due to the syndrome of inappropriate antidiuretic hormone (SIADH).[47][48]
QT prolongation: Fluoxetine can prolong the QT interval, possibly leading to torsade de pointes. The drug should be used cautiously in patients with an increased risk of QT prolongation.[37]
Cognitive impairment: Fluoxetine can potentially impair cognitive function and motor skills. Per manufacturer labeling, caution should be exercised when performing tasks requiring alertness, such as operating machinery. On the contrary, some studies suggest that fluoxetine may enhance cognitive function in patients with dementia. Individual patient assessment and MMSE may be required if there is doubt regarding deteriorating cognition.[49]
Sexual dysfunction: SSRIs, including fluoxetine, can lead to sexual side effects in both males and females. In males, these may include delayed ejaculation, decreased libido, and erectile dysfunction. This ADR can be utilized for patients with from premature ejaculation. Females may experience decreased libido or anorgasmia.[50][51]
Monitoring
A thorough assessment of depression and suicidal risk, particularly at the beginning of therapy or when doses are changed, anxiety/panic attacks, social functioning, mania/mood lability, and features of serotonin syndrome.[38][52] The PHQ-9 (Patient Health Questionnaire-9) and HAM-D/HDRS (Hamilton Depression Rating Scale) should be monitored.[53][54][55]
No routine laboratory testing is necessary for healthy individuals. However, in older and population-specific patients, clinicians may order blood glucose and liver function tests. In addition, prescribers may order an ECG for patients with risk factors for QT prolongation and ventricular arrhythmias. Pediatric patients' height and weight should be monitored periodically when receiving fluoxetine.
The American Society of Regional Anesthesia (ASRA) suggests a washout period of approximately 5 weeks before interventional spine and pain procedures due to the long half-life of fluoxetine to decrease the risk of bleeding.[56]
Toxicity
Fluoxetine is rarely lethal in monotherapy overdose. However, when taken with alcohol, it may cause ataxia and respiratory depression. The drug may cause serotonin syndrome (clinical constellation of changes in mental status, autonomic instability, and neuromuscular abnormalities) when taken in excessive amounts or combined with other agents that increase serotonin levels.[57][58]
Management of Overdose
In the case of SSRI overdose, the goal is to provide supportive therapy. This support can be in the form of airway protection, serial ECGs to monitor for cardiotoxicity, administration of benzodiazepines for sedation, and GI decontamination with activated charcoal. Serotonin syndrome is treatable with the administration of cyproheptadine.[59][60]
Enhancing Healthcare Team Outcomes
Fluoxetine is a commonly prescribed antidepressant by physicians and advanced practice practitioners, psychiatrists, and internists, but effective therapy requires the effort of an interprofessional team. When treating pregnant women during the third trimester with fluoxetine, the prescriber should consider the potential benefits and risks of treatment. In addition, clinicians should consider that women who stopped antidepressant medication while pregnant were more likely to experience a relapse of MDD than women who continued to use antidepressant drugs.
Nursing staff and prescribers should monitor children and adolescent patients for suicidal ideation, especially when starting fluoxetine or increasing doses. Nursing staff, particularly those with specialty training in psychiatric health, can counsel patients on proper dosing and administration. For example, it is crucial to educate patients that they should not combine the drug with alcohol or other antidepressants. The patient should have regular follow-ups regarding depression and suicidal thoughts. The pharmacist should verify dosing, especially check for drug interactions, given fluoxetine's extensive list of interactions, and report these to the prescriber if present.
All interprofessional team members are responsible for monitoring the patient, offering counsel, and noting any patient status changes. If they observe any issues, they should be documented in the patient's health record for all team members to follow, and the new information should be communicated to other team members so changes can be made if necessary. With close monitoring from all team members, fluoxetine can be an effective drug for numerous psychiatric conditions, including major depression. An interprofessional approach involving open communication between clinicians, specialists, and pharmacists can achieve optimal outcomes related to fluoxetine therapy while mitigating adverse effects.
References
Mikocka-Walus A, Prady SL, Pollok J, Esterman AJ, Gordon AL, Knowles S, Andrews JM. Adjuvant therapy with antidepressants for the management of inflammatory bowel disease. The Cochrane database of systematic reviews. 2019 Apr 12:4(4):CD012680. doi: 10.1002/14651858.CD012680.pub2. Epub 2019 Apr 12 [PubMed PMID: 30977111]
Level 1 (high-level) evidenceDhenain T, Côté F, Coman T. Serotonin and orthodontic tooth movement. Biochimie. 2019 Jun:161():73-79. doi: 10.1016/j.biochi.2019.04.002. Epub 2019 Apr 3 [PubMed PMID: 30953672]
Burch R. Antidepressants for Preventive Treatment of Migraine. Current treatment options in neurology. 2019 Mar 21:21(4):18. doi: 10.1007/s11940-019-0557-2. Epub 2019 Mar 21 [PubMed PMID: 30895388]
Crone C, Fochtmann LJ, Attia E, Boland R, Escobar J, Fornari V, Golden N, Guarda A, Jackson-Triche M, Manzo L, Mascolo M, Pierce K, Riddle M, Seritan A, Uniacke B, Zucker N, Yager J, Craig TJ, Hong SH, Medicus J. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders. The American journal of psychiatry. 2023 Feb 1:180(2):167-171. doi: 10.1176/appi.ajp.23180001. Epub [PubMed PMID: 36722117]
Level 1 (high-level) evidenceLi X, Li J, Li X, Wang J, Dai H, Wang J. Effectiveness and safety of fluoxetine for premature ejaculation: Protocol for a systematic review. Medicine. 2019 Feb:98(7):e14481. doi: 10.1097/MD.0000000000014481. Epub [PubMed PMID: 30762772]
Level 1 (high-level) evidenceSlee A, Nazareth I, Bondaronek P, Liu Y, Cheng Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet (London, England). 2019 Feb 23:393(10173):768-777. doi: 10.1016/S0140-6736(18)31793-8. Epub 2019 Jan 31 [PubMed PMID: 30712879]
Level 1 (high-level) evidenceMartin A, Naunton M, Kosari S, Peterson G, Thomas J, Christenson JK. Treatment Guidelines for PTSD: A Systematic Review. Journal of clinical medicine. 2021 Sep 15:10(18):. doi: 10.3390/jcm10184175. Epub 2021 Sep 15 [PubMed PMID: 34575284]
Level 1 (high-level) evidenceHiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacology & therapeutics. 2000 Jan:85(1):11-28 [PubMed PMID: 10674711]
Robertson OD, Coronado NG, Sethi R, Berk M, Dodd S. Putative neuroprotective pharmacotherapies to target the staged progression of mental illness. Early intervention in psychiatry. 2019 Oct:13(5):1032-1049. doi: 10.1111/eip.12775. Epub 2019 Jan 28 [PubMed PMID: 30690898]
Cao B, Zhu J, Zuckerman H, Rosenblat JD, Brietzke E, Pan Z, Subramanieapillai M, Park C, Lee Y, McIntyre RS. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review. Progress in neuro-psychopharmacology & biological psychiatry. 2019 Jun 8:92():109-117. doi: 10.1016/j.pnpbp.2019.01.002. Epub 2019 Jan 3 [PubMed PMID: 30611836]
Level 1 (high-level) evidenceDelavenne X, Magnin M, Basset T, Piot M, Mallouk N, Ressnikoff D, Garcin A, Laporte S, Garnier P, Mismetti P. Investigation of drug-drug interactions between clopidogrel and fluoxetine. Fundamental & clinical pharmacology. 2013 Dec:27(6):683-9. doi: 10.1111/fcp.12021. Epub 2013 Feb 17 [PubMed PMID: 23413998]
Level 1 (high-level) evidenceDeodhar M, Rihani SBA, Darakjian L, Turgeon J, Michaud V. Assessing the Mechanism of Fluoxetine-Mediated CYP2D6 Inhibition. Pharmaceutics. 2021 Jan 23:13(2):. doi: 10.3390/pharmaceutics13020148. Epub 2021 Jan 23 [PubMed PMID: 33498694]
Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review. Psychotherapy and psychosomatics. 2015:84(2):72-81 [PubMed PMID: 25721705]
Level 1 (high-level) evidenceAndrade C. Psychotropic Drugs With Long Half-Lives: Implications for Drug Discontinuation, Occasional Missed Doses, Dosing Interval, and Pregnancy Planning. The Journal of clinical psychiatry. 2022 Aug 1:83(4):. pii: 22f14593. doi: 10.4088/JCP.22f14593. Epub 2022 Aug 1 [PubMed PMID: 35921503]
Wagstaff AJ, Goa KL. Once-weekly fluoxetine. Drugs. 2001:61(15):2221-8; discussion 2229-30 [PubMed PMID: 11772132]
Kauffman KM, Dolata J, Figueroa M, Gunzler D, Huml A, Pencak J, Sajatovic M, Sehgal AR. Directly Observed Weekly Fluoxetine for Major Depressive Disorder Among Hemodialysis Patients: A Single-Arm Feasibility Trial. Kidney medicine. 2022 Mar:4(3):100413. doi: 10.1016/j.xkme.2022.100413. Epub 2022 Jan 17 [PubMed PMID: 35386606]
Level 2 (mid-level) evidenceLarsen ER, Damkier P, Pedersen LH, Fenger-Gron J, Mikkelsen RL, Nielsen RE, Linde VJ, Knudsen HE, Skaarup L, Videbech P, Danish Psychiatric Society, Danish Society of Obstetrics and Gynecology, Danish Paediatric Society, Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding. Acta psychiatrica Scandinavica. Supplementum. 2015:(445):1-28. doi: 10.1111/acps.12479. Epub [PubMed PMID: 26344706]
. Fluoxetine. Drugs and Lactation Database (LactMed®). 2006:(): [PubMed PMID: 30000245]
Walter HJ, Abright AR, Bukstein OG, Diamond J, Keable H, Ripperger-Suhler J, Rockhill C. Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Major and Persistent Depressive Disorders. Journal of the American Academy of Child and Adolescent Psychiatry. 2023 May:62(5):479-502. doi: 10.1016/j.jaac.2022.10.001. Epub 2022 Oct 21 [PubMed PMID: 36273673]
Level 1 (high-level) evidenceSolmi M, Fornaro M, Ostinelli EG, Zangani C, Croatto G, Monaco F, Krinitski D, Fusar-Poli P, Correll CU. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects. World psychiatry : official journal of the World Psychiatric Association (WPA). 2020 Jun:19(2):214-232. doi: 10.1002/wps.20765. Epub [PubMed PMID: 32394557]
Level 1 (high-level) evidenceGutsmiedl K, Krause M, Bighelli I, Schneider-Thoma J, Leucht S. How well do elderly patients with major depressive disorder respond to antidepressants: a systematic review and single-group meta-analysis. BMC psychiatry. 2020 Mar 4:20(1):102. doi: 10.1186/s12888-020-02514-2. Epub 2020 Mar 4 [PubMed PMID: 32131786]
Level 1 (high-level) evidenceMullen S. Major depressive disorder in children and adolescents. The mental health clinician. 2018 Nov:8(6):275-283. doi: 10.9740/mhc.2018.11.275. Epub 2018 Nov 1 [PubMed PMID: 30397569]
Bahar MA, Kamp J, Borgsteede SD, Hak E, Wilffert B. The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine. British journal of clinical pharmacology. 2018 Dec:84(12):2704-2715. doi: 10.1111/bcp.13741. Epub 2018 Sep 24 [PubMed PMID: 30248178]
Level 1 (high-level) evidenceWichniak A, Wierzbicka A, Walęcka M, Jernajczyk W. Effects of Antidepressants on Sleep. Current psychiatry reports. 2017 Aug 9:19(9):63. doi: 10.1007/s11920-017-0816-4. Epub 2017 Aug 9 [PubMed PMID: 28791566]
Manning T, Bartow C, Dunlap M, Kiehl R, Kneale H, Walker A. Reversible Cerebral Vasoconstriction Syndrome Associated With Fluoxetine. Journal of the Academy of Consultation-Liaison Psychiatry. 2021 Nov-Dec:62(6):634-644. doi: 10.1016/j.jaclp.2021.07.013. Epub 2021 Aug 8 [PubMed PMID: 34371244]
Laban T, Larroche C, Comparon C, Dhôte R, Degos B. Fluoxetine-induced chorea. Revue neurologique. 2021 Oct:177(8):1010-1011. doi: 10.1016/j.neurol.2020.12.007. Epub 2021 Jun 18 [PubMed PMID: 34148736]
Naguy A, Moodliar-Rensburg S, Elsori DH, Alamiri B. Fluoxetine-Induced "Rabbit Syndrome" in a Child With Juvenile Obsessive-Compulsive Disorder. American journal of therapeutics. 2022 May-Jun 01:29(3):e363-e364. doi: 10.1097/MJT.0000000000001195. Epub 2020 May 5 [PubMed PMID: 32384313]
Edinoff AN, Fort JM, Woo JJ, Causey CD, Burroughs CR, Cornett EM, Kaye AM, Kaye AD. Selective Serotonin Reuptake Inhibitors and Clozapine: Clinically Relevant Interactions and Considerations. Neurology international. 2021 Sep 1:13(3):445-463. doi: 10.3390/neurolint13030044. Epub 2021 Sep 1 [PubMed PMID: 34564289]
. 2021 ACMT Annual Scientific Meeting Abstracts-Virtual. Journal of medical toxicology : official journal of the American College of Medical Toxicology. 2021 Mar 31:17(2):93-153. doi: 10.1007/s13181-021-00832-9. Epub 2021 Mar 31 [PubMed PMID: 33791944]
Wei A, Peng J, Gu Z, Li J. QTc prolongation and torsades de pointes due to a coadministration of fluoxetine and amiodarone in a patient with implantable cardioverter-defibrillator: Case report and review of the literature. Medicine. 2017 Dec:96(49):e9071. doi: 10.1097/MD.0000000000009071. Epub [PubMed PMID: 29245320]
Level 3 (low-level) evidenceDent LA, Orrock MW. Warfarin-fluoxetine and diazepam-fluoxetine interaction. Pharmacotherapy. 1997 Jan-Feb:17(1):170-2 [PubMed PMID: 9017779]
Level 3 (low-level) evidenceSpina E, Barbieri MA, Cicala G, Bruno A, de Leon J. Clinically relevant drug interactions between newer antidepressants and oral anticoagulants. Expert opinion on drug metabolism & toxicology. 2020 Jan:16(1):31-44. doi: 10.1080/17425255.2020.1700952. Epub 2019 Dec 10 [PubMed PMID: 31795773]
Level 3 (low-level) evidencede Abajo FJ, Montero D, Rodríguez LA, Madurga M. Antidepressants and risk of upper gastrointestinal bleeding. Basic & clinical pharmacology & toxicology. 2006 Mar:98(3):304-10 [PubMed PMID: 16611206]
Level 3 (low-level) evidenceZaccara G, Franco V. Pharmacokinetic Interactions Between Antiseizure and Psychiatric Medications. Current neuropharmacology. 2023:21(8):1666-1690. doi: 10.2174/1570159X20666220524121645. Epub [PubMed PMID: 35611779]
Park SH, Wackernah RC, Stimmel GL. Serotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants? Journal of pharmacy practice. 2014 Feb:27(1):71-8. doi: 10.1177/0897190013504957. Epub 2013 Oct 23 [PubMed PMID: 24153222]
Mazhar F, Akram S, Haider N, Ahmed R. Overlapping of Serotonin Syndrome with Neuroleptic Malignant Syndrome due to Linezolid-Fluoxetine and Olanzapine-Metoclopramide Interactions: A Case Report of Two Serious Adverse Drug Effects Caused by Medication Reconciliation Failure on Hospital Admission. Case reports in medicine. 2016:2016():7128909. doi: 10.1155/2016/7128909. Epub 2016 Jun 28 [PubMed PMID: 27433163]
Level 3 (low-level) evidenceTisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC. 2016 May:149(3):139-52. doi: 10.1177/1715163516641136. Epub 2016 Apr 8 [PubMed PMID: 27212965]
Selph SS, McDonagh MS. Depression in Children and Adolescents: Evaluation and Treatment. American family physician. 2019 Nov 15:100(10):609-617 [PubMed PMID: 31730312]
Edinoff AN, Akuly HA, Hanna TA, Ochoa CO, Patti SJ, Ghaffar YA, Kaye AD, Viswanath O, Urits I, Boyer AG, Cornett EM, Kaye AM. Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review. Neurology international. 2021 Aug 5:13(3):387-401. doi: 10.3390/neurolint13030038. Epub 2021 Aug 5 [PubMed PMID: 34449705]
Level 3 (low-level) evidenceRiggin L, Frankel Z, Moretti M, Pupco A, Koren G. The fetal safety of fluoxetine: a systematic review and meta-analysis. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC. 2013 Apr:35(4):362-369. doi: 10.1016/S1701-2163(15)30965-8. Epub [PubMed PMID: 23660045]
Level 2 (mid-level) evidenceAnderson KN, Lind JN, Simeone RM, Bobo WV, Mitchell AA, Riehle-Colarusso T, Polen KN, Reefhuis J. Maternal Use of Specific Antidepressant Medications During Early Pregnancy and the Risk of Selected Birth Defects. JAMA psychiatry. 2020 Dec 1:77(12):1246-1255. doi: 10.1001/jamapsychiatry.2020.2453. Epub [PubMed PMID: 32777011]
Chi SH, Jeong HG, Lee S, Oh SY, Kim SH. Effects of Psychotropic Drugs on Seizure Threshold during Electroconvulsive Therapy. Psychiatry investigation. 2017 Sep:14(5):647-655. doi: 10.4306/pi.2017.14.5.647. Epub 2017 Sep 11 [PubMed PMID: 29042890]
Andrade C. Fluoxetine for Stroke: A Mixed Bag of Outcomes. The Journal of clinical psychiatry. 2021 Jun 8:82(3):. pii: 21f14106. doi: 10.4088/JCP.21f14106. Epub 2021 Jun 8 [PubMed PMID: 34106530]
Agrawal R, Almoghrabi A, Attar BM, Gandhi S. Fluoxetine-induced Stevens-Johnson syndrome and liver injury. Journal of clinical pharmacy and therapeutics. 2019 Feb:44(1):115-118. doi: 10.1111/jcpt.12760. Epub 2018 Oct 8 [PubMed PMID: 30296343]
Akaltun İ, Ayaydin H. Fluoxetine-related mania in an adolescent girl diagnosed with selective mutism: A case report. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists. 2020 Mar:12(1):e12367. doi: 10.1111/appy.12367. Epub 2019 Jun 20 [PubMed PMID: 31222962]
Level 3 (low-level) evidenceCostagliola C, Parmeggiani F, Semeraro F, Sebastiani A. Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure. Current neuropharmacology. 2008 Dec:6(4):293-310. doi: 10.2174/157015908787386104. Epub [PubMed PMID: 19587851]
Gandhi S, Shariff SZ, Al-Jaishi A, Reiss JP, Mamdani MM, Hackam DG, Li L, McArthur E, Weir MA, Garg AX. Second-Generation Antidepressants and Hyponatremia Risk: A Population-Based Cohort Study of Older Adults. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2017 Jan:69(1):87-96. doi: 10.1053/j.ajkd.2016.08.020. Epub 2016 Oct 20 [PubMed PMID: 27773479]
Seshadri M, Thalitaya MD, Simon T, Odelola C, Enow H. Antidepressants and Hyponatremia in a patient with Colectomy - a Case Report. Psychiatria Danubina. 2017 Sep:29(Suppl 3):610-614 [PubMed PMID: 28953839]
Level 3 (low-level) evidenceZhang L, Liu X, Li T, Xu B, Fu B. Fluoxetine May Enhance VEGF, BDNF and Cognition in Patients with Vascular Cognitive Impairment No Dementia: An Open-Label Randomized Clinical Study. Neuropsychiatric disease and treatment. 2021:17():3819-3825. doi: 10.2147/NDT.S334647. Epub 2021 Dec 29 [PubMed PMID: 35002241]
Level 1 (high-level) evidenceCooper K, Martyn-St James M, Kaltenthaler E, Dickinson K, Cantrell A. Interventions to treat premature ejaculation: a systematic review short report. Health technology assessment (Winchester, England). 2015 Mar:19(21):1-180, v-vi. doi: 10.3310/hta19210. Epub [PubMed PMID: 25768099]
Level 1 (high-level) evidenceJing E, Straw-Wilson K. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review. The mental health clinician. 2016 Jul:6(4):191-196. doi: 10.9740/mhc.2016.07.191. Epub 2016 Jun 29 [PubMed PMID: 29955469]
Lee-Kelland R, Zehra S, Mappa P. Fluoxetine overdose in a teenager resulting in serotonin syndrome, seizure and delayed onset rhabdomyolysis. BMJ case reports. 2018 Oct 8:2018():. pii: bcr-2018-225529. doi: 10.1136/bcr-2018-225529. Epub 2018 Oct 8 [PubMed PMID: 30301727]
Level 3 (low-level) evidenceSharp R. The Hamilton Rating Scale for Depression. Occupational medicine (Oxford, England). 2015 Jun:65(4):340. doi: 10.1093/occmed/kqv043. Epub [PubMed PMID: 25972613]
Arroll B, Goodyear-Smith F, Crengle S, Gunn J, Kerse N, Fishman T, Falloon K, Hatcher S. Validation of PHQ-2 and PHQ-9 to screen for major depression in the primary care population. Annals of family medicine. 2010 Jul-Aug:8(4):348-53. doi: 10.1370/afm.1139. Epub [PubMed PMID: 20644190]
Level 1 (high-level) evidenceBeard C, Hsu KJ, Rifkin LS, Busch AB, Björgvinsson T. Validation of the PHQ-9 in a psychiatric sample. Journal of affective disorders. 2016 Mar 15:193():267-73. doi: 10.1016/j.jad.2015.12.075. Epub 2015 Dec 31 [PubMed PMID: 26774513]
Level 1 (high-level) evidenceNarouze S, Benzon HT, Provenzano D, Buvanendran A, De Andres J, Deer T, Rauck R, Huntoon MA. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition): Guidelines From the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Regional anesthesia and pain medicine. 2018 Apr:43(3):225-262. doi: 10.1097/AAP.0000000000000700. Epub [PubMed PMID: 29278603]
Nelson LS, Erdman AR, Booze LL, Cobaugh DJ, Chyka PA, Woolf AD, Scharman EJ, Wax PM, Manoguerra AS, Christianson G, Caravati EM, Troutman WG. Selective serotonin reuptake inhibitor poisoning: An evidence-based consensus guideline for out-of-hospital management. Clinical toxicology (Philadelphia, Pa.). 2007 May:45(4):315-32 [PubMed PMID: 17486478]
Level 1 (high-level) evidencePatel DD, Galarneau D. Serotonin Syndrome With Fluoxetine: Two Case Reports. Ochsner journal. 2016 Winter:16(4):554-557 [PubMed PMID: 27999518]
Level 3 (low-level) evidenceBruggeman C, O'Day CS. Selective Serotonin Reuptake Inhibitor Toxicity. StatPearls. 2024 Jan:(): [PubMed PMID: 30521236]
Barbey JT, Roose SP. SSRI safety in overdose. The Journal of clinical psychiatry. 1998:59 Suppl 15():42-8 [PubMed PMID: 9786310]